IL-16 as a target for diagnosis and therapy of hematological malignancies and solid tumors
The present invention relates to the field of diagnosis and therapy of hematological malignancies, such as multiple myeloma, as well as solid tumors based on cytokine interleukin-16 (IL-16) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that IL-16 is expressed and secreted at high levels by myeloma cells. Most importantly, the inventors have demonstrated for the first time that IL-16 supports the proliferation of the malignant cells. Therefore, this cytokine represents a particularly advantageous target in cancer therapy and diagnosis.
1 . A method of treating a hematological malignancy or a solid tumor or of preventing progression from a premalignancy to a malignancy, comprising administering to a subject an effective amount of an agent capable of specifically targeting IL-16.
2 . The method of claim 1 , wherein the hematological malignancy is multiple myeloma (MM), indolent myeloma, smoldering myeloma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), cutaneous T-cell leukemia (e.g., Sezary syndrome), hairy cell leukemia, Hodgkin's disease, Non-Hodgkin lymphoma, myelodysplastic syndrome (MDS) or myeloproliferative disease.
3 . The method of claim 1 , wherein the premalignancy is monoclonal gammopathy of undetermined significance (MGUS).
4 . The method of claim 1 , wherein the solid tumor is colon carcinoma, breast carcinoma, lung carcinoma (small-cell lung cancer and non-small cell lung cancer), head and neck cancer, glioblastoma multiforme, sarcoma, cervical cancer, endometrial cancer, cancer of the pancreas, thyroid, stomach, bladder, skin, breast, prostate, ovary, kidney, or liver.
5 . The method of claim 1 , wherein the agent is an anti-IL-16 antibody, a soluble 1L-16 receptor or an antibody directed against an IL-16 receptor.
6 . The method of claim 5 , wherein the agent is an anti-IL-16 antibody or a soluble IL-16 receptor and it is coupled to an active compound selected from the group comprising a cytotoxic compound.
7 . The method of claim 1 , wherein the agent targeting IL-16 is an IL-16 receptor antagonist or an IL-16 TRAP.
8 . The method of claim 1 , wherein the agent targeting IL-16 inhibits IL-16 expression on the RNA and/or protein level.
9 . The method of claim 8 , wherein the agent is inhibitory RNA or antisense RNA.
10 - 19 . (canceled)